Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases

Clinical Immunology : the Official Journal of the Clinical Immunology Society
Eric EspinosaCristina Bulai Livideanu

Abstract

There is no therapeutic agent approved in cutaneous mastocytosis and mast cell activation syndrome. We report the efficacy of hydroxychloroquine in four patients with cutaneous mastocytosis (n = 2) and mast cell activation syndrome (n = 2). We show that this molecule reduces the long-term survival of primary human mast cells, interferes with lysosome function and leads to the accumulation of non-functional tryptase in the mast cell granules. Furthermore, hydroxychloroquine decreases the production of pro-inflammatory mediators.

Citations

Sep 4, 2021·Dermatology and Therapy·Mark C Marchitto, Anna L Chien

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Related Papers

Klinicheskaia laboratornaia diagnostika
A M Popov, A F Tomilov
Polski tygodnik lekarski
A Pawłowicz, W Droszcz
The Journal of Investigative Dermatology
M D Tharp
La Tunisie médicale
V DemoulinB Jomaa
Archives of Dermatology
R S HOMER
© 2022 Meta ULC. All rights reserved